Loading stock data…
$21.67-0.55 (-2.48%)
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
Tango Therapeutics, Inc. in the Healthcare sector is trading at $21.67 with a market capitalization of $3.7B. Wall Street consensus targets $45.18 (11 analysts), implying a +108.5% move over the next 12 months. The stock is currently 37% below its 52-week high of $34.39, remaining 0.7% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0↓ | $53.81M↑ | $3.18M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$59.78M↓ | -$48.77M↓ | -$41.86M↓ | $14.07M↑ | -$40.97M |
| Net Income | -$55.34M↓ | -$45.51M↓ | -$38.75M↓ | $15.88M↑ | -$38.85M |
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase...